"... If India has to produce and deliver 130 crore doses to Indian people in one year time, my opinion is that India would need to invest in manufacturing facilities to the extent of roughly Rs 3,000 to Rs 5,000 crore to create additional capacity to make it happen," Patel said.
These vaccines are coming from a very difficult platform, and as a result, the cost of the vaccine is going to be significantly higher compared to many other vaccines, so there is going to be a requirement to think about how are we going to fund this, he said in a panel discussion on 'Race for COVID Vaccine: More than just a Cure' at an AIMA event.
Emphasizing that while the vaccine will play an important role in the control of the pandemic, Patel said: "Vaccine alone in my opinion is not the solution to the problem. We need the vaccine and also we need more treatment protocols to make sure we are able to take care of it, because I think the way the vaccine trials are designed currently globally, there is not going to be a possibility of immunity in 100 per cent of people."
Moreover, the requirement of the vaccine doses is going to be very high. Given the fact almost all vaccines are going to work at least two doses, if we look at India's population and decide to immunise 50 per cent of the population, we would require over 130 crore doses and that's not the capacity anybody has. Even if people have the capacity to produce, it cannot happen in one day. It can only happen over a long period, Patel said.
Another challenge we would have is "how long the immunity will last with this vaccine? If the vaccine is going to give a long-term immunity, it will be wonderful, but if it provides short-term immunity then we will have to keep on immunising people again and again," he added.
A vaccine is definitely needed to control the spread of this disease, but the vaccine alone is not enough, and other efforts such as social distancing, wearing mask, isolating and testing people will continue to remain important, Patel said.
Speaking about logistics of the distribution system, Patel said the country needs to have a very strong distribution system. Because of the number of doses, "there could be challenges of glass vials supply, though I don't see challenges to supply of syringes", he added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.